XMT-1660 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer+9 More
XMT-1660 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the effects of XMT-1660 on advanced solid tumors.

Eligible Conditions
  • Breast Cancer
  • Endometrial Cancer
  • Fallopian Tubes Cancer
  • Breast Cancer (Triple Negative Breast Cancer (TNBC))
  • Malignant Neoplasms
  • Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Breast Cancer

Study Objectives

4 Primary · 10 Secondary · Reporting Duration: 3 years

17 months
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with XMT-1660 during the first cycle of treatment (Dose Escalation)
3 years
Apparent terminal elimination half-life of XMT-1660 (Dose Expansion)
Area under the concentration-time curve of XMT-1660 (AUC) (Dose Expansion)
Assess antidrug antibodies (ADA) and neutralizing antibodies (nAB) (Dose Expansion)
Incidence of adverse events (Dose Escalation and Dose Expansion)
Maximum observed plasma concentration of XMT-1660 (Cmax) (Dose Expansion)
Systemic clearance of XMT-1660 (Dose Expansion)
Time of maximum observed plasma concentration of XMT-1660 (Tmax) (Dose Expansion)
Trough concentration of XMT-1660 (Ctrough) (Dose Expansion)
Volume of Distribution (Dose Expansion)
Year 3
Duration of response (DOR) (Dose Escalation)
Objective Response Rate (ORR) (Dose Escalation)
approximately 3 years
Duration of response (DOR) (Dose Expansion)
Objective Response Rate (ORR) (Dose Expansion)

Trial Safety

Safety Progress

1 of 3

Other trials for Breast Cancer

Trial Design

1 Treatment Group

XMT-1660
1 of 1
Experimental Treatment

166 Total Participants · 1 Treatment Group

Primary Treatment: XMT-1660 · No Placebo Group · Phase 1

XMT-1660
Drug
Experimental Group · 1 Intervention: XMT-1660 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Mersana TherapeuticsLead Sponsor
8 Previous Clinical Trials
1,308 Total Patients Enrolled
Dr. Shin, MDStudy DirectorMersana Therapeutics
Ellie Im, MDStudy DirectorMersana Therapeutics
1 Previous Clinical Trials
120 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a solid tumor and have disease progression after treatment with anti-cancer therapies known to confer benefit or are intolerant to treatment.
You have a performance status of 0 or 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.